Literature DB >> 24331147

Current readings: improvements in intensity-modulated radiation therapy for malignant pleural mesothelioma.

Kenneth E Rosenzweig1.   

Abstract

The treatment of malignant pleural mesothelioma with radiation therapy has always been a technical challenge. Early experience with intensity-modulated radiation therapy demonstrated troubling toxicity. Recent reports from institutions have demonstrated that with greater experience, intensity-modulated radiation therapy can be delivered safely, both in the setting of pneumonectomy or pleurectomy. After pneumonectomy, the dose to the contralateral lung must be minimized, preferably with a volume of lung receiving 20 Gy (V20) to less than 5% and a mean lung dose of approximately 10%. In the setting of 2 intact lungs, the mean lung dose can be as high as 20 Gy. Expected rates of grade 3 or worse radiation pneumonitis are 12%-20%. The rates of fatal pneumonitis are approximately 3%-8% in these studies, which demonstrate the considerable toxicity of treatment, even with improved technique.
© 2013 Published by Elsevier Inc.

Entities:  

Keywords:  intensity-modulated radiation therapy; mesothelioma; radiation pneumonitis; radiotherapy

Mesh:

Year:  2013        PMID: 24331147     DOI: 10.1053/j.semtcvs.2013.10.004

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  3 in total

Review 1.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.

Authors:  Weiquan Zhang; Xinshu Wu; Licun Wu; Weidong Zhang; Xiaogang Zhao
Journal:  Ann Transl Med       Date:  2015-08

Review 3.  Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.

Authors:  Kana Hashimoto; Yusuke Okuma; Yukio Hosomi; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2016-09-06       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.